• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma.

作者信息

Rampotas Alexandros, Sangha Gina, Collins Graham P

机构信息

Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK.

出版信息

Ther Adv Hematol. 2021 Oct 30;12:20406207211053120. doi: 10.1177/20406207211053120. eCollection 2021.

DOI:10.1177/20406207211053120
PMID:34733463
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8558790/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4859/8558790/10d320d1941d/10.1177_20406207211053120-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4859/8558790/1569646dd36c/10.1177_20406207211053120-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4859/8558790/a6128bb4635a/10.1177_20406207211053120-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4859/8558790/9b8ca0d421ff/10.1177_20406207211053120-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4859/8558790/10d320d1941d/10.1177_20406207211053120-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4859/8558790/1569646dd36c/10.1177_20406207211053120-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4859/8558790/a6128bb4635a/10.1177_20406207211053120-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4859/8558790/9b8ca0d421ff/10.1177_20406207211053120-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4859/8558790/10d320d1941d/10.1177_20406207211053120-fig4.jpg

相似文献

1
Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma.将细胞疗法和双特异性抗体整合到复发弥漫性大B细胞淋巴瘤的治疗路径中。
Ther Adv Hematol. 2021 Oct 30;12:20406207211053120. doi: 10.1177/20406207211053120. eCollection 2021.
2
Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.新旧免疫疗法：造血干细胞移植、嵌合抗原受体 T 细胞和双特异性抗体治疗复发/难治性弥漫性大 B 细胞淋巴瘤。
Curr Hematol Malig Rep. 2021 Feb;16(1):72-81. doi: 10.1007/s11899-021-00610-y. Epub 2021 Feb 22.
3
Investigational drugs for the treatment of diffuse large B-cell lymphoma.治疗弥漫性大 B 细胞淋巴瘤的研究性药物。
Expert Opin Investig Drugs. 2021 Jan;30(1):25-38. doi: 10.1080/13543784.2021.1855140. Epub 2020 Dec 21.
4
Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas.双特异性抗体：B细胞淋巴瘤的研发、临床疗效及毒性综述
J Pers Med. 2021 Apr 29;11(5):355. doi: 10.3390/jpm11050355.
5
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.双特异性 T 细胞衔接器（BiTE）抗体构建药物blinatumomab 治疗复发/难治性非霍奇金淋巴瘤患者：I 期研究的最终结果。
J Clin Oncol. 2016 Apr 1;34(10):1104-11. doi: 10.1200/JCO.2014.59.1586. Epub 2016 Feb 16.
6
Blinatumomab: a novel therapy for the treatment of non-Hodgkin's lymphoma.Blinatumomab：一种治疗非霍奇金淋巴瘤的新型疗法。
Expert Rev Hematol. 2019 Nov;12(11):909-918. doi: 10.1080/17474086.2019.1676717. Epub 2019 Oct 16.
7
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.双特异性T细胞衔接器（BiTE）抗体博纳吐单抗用于复发/难治性弥漫性大B细胞淋巴瘤的2期研究。
Blood. 2016 Mar 17;127(11):1410-6. doi: 10.1182/blood-2015-06-651380. Epub 2016 Jan 11.
8
Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma.复发/难治性弥漫性大B细胞淋巴瘤接受博纳吐单抗治疗后完全缓解的持久性
Leuk Lymphoma. 2020 Nov;61(11):2767-2770. doi: 10.1080/10428194.2020.1783442. Epub 2020 Jul 7.
9
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.塔法西单抗联合来那度胺治疗复发或难治性弥漫性大 B 细胞淋巴瘤（L-MIND）：一项多中心、前瞻性、单臂、2 期研究。
Lancet Oncol. 2020 Jul;21(7):978-988. doi: 10.1016/S1470-2045(20)30225-4. Epub 2020 Jun 5.
10
Blinatumomab in relapsed/refractory diffuse large B cell lymphoma.复发/难治性弥漫性大B细胞淋巴瘤中的博纳吐单抗
Ann Hematol. 2017 Oct;96(10):1759-1762. doi: 10.1007/s00277-017-3088-5. Epub 2017 Aug 5.

引用本文的文献

1
Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia.改善亚洲难治性或复发性弥漫性大B细胞淋巴瘤患者获得嵌合抗原受体T细胞治疗的机会。
Discov Oncol. 2025 Feb 14;16(1):181. doi: 10.1007/s12672-025-01860-5.
2
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer.接受tarlatamab（一种靶向δ样配体3的双特异性T细胞衔接器免疫疗法）治疗的既往接受过治疗的小细胞肺癌患者不良事件的实际管理。
Cancer. 2025 Feb 1;131(3):e35738. doi: 10.1002/cncr.35738.
3

本文引用的文献

1
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.Loncastuximab tesirine 治疗复发或难治性弥漫性大 B 细胞淋巴瘤（LOTIS-2）：一项多中心、开放标签、单臂、2 期临床试验。
Lancet Oncol. 2021 Jun;22(6):790-800. doi: 10.1016/S1470-2045(21)00139-X. Epub 2021 May 11.
2
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.戈利木单抗，一种新型、双价 CD20 靶向 T 细胞衔接双特异性抗体，在复发或难治性 B 细胞淋巴瘤中诱导持久完全缓解：一项 I 期试验。
J Clin Oncol. 2021 Jun 20;39(18):1959-1970. doi: 10.1200/JCO.20.03175. Epub 2021 Mar 19.
3
Real-world evaluation of health-related quality of life in patients with diffuse large B-cell lymphoma based on a multinational survey.
基于一项跨国调查对弥漫性大B细胞淋巴瘤患者健康相关生活质量的真实世界评估。
Front Oncol. 2024 Jun 24;14:1402992. doi: 10.3389/fonc.2024.1402992. eCollection 2024.
4
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7.ZUMA-7 中二线 axicabtagene ciloleucel 或标准治疗后后续抗淋巴瘤治疗的结果。
Blood Adv. 2024 Jun 11;8(11):2982-2990. doi: 10.1182/bloodadvances.2023011532.
5
nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma.基于纳米颗粒的 T 细胞成像可以预测实验性神经胶质瘤中过继性 T 细胞治疗的反应。
Theranostics. 2023 Sep 25;13(15):5170-5182. doi: 10.7150/thno.87248. eCollection 2023.
6
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma.B 细胞非霍奇金淋巴瘤肿瘤内调节性 T 细胞的异质性。
Blood Adv. 2023 Dec 12;7(23):7216-7230. doi: 10.1182/bloodadvances.2023010158.
7
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.莫努匹韦单抗单药治疗复发/难治性弥漫性大 B 细胞淋巴瘤患者具有疗效且可耐受。
Blood Adv. 2023 Sep 12;7(17):4926-4935. doi: 10.1182/bloodadvances.2022009260.
8
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial.口服 PI3Kδ 抑制剂 Linperlisib 治疗复发/难治性滤泡性淋巴瘤：一项 II 期、单臂、开放标签临床试验。
Clin Cancer Res. 2023 Apr 14;29(8):1440-1449. doi: 10.1158/1078-0432.CCR-22-2939.
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.依帕珠单抗针对 DLBCL、FL 和 MCL 患者的恶性 B 细胞具有强大的抗肿瘤活性，无论先前是否接受过 CD20 单克隆抗体治疗。
Blood Cancer J. 2021 Feb 18;11(2):38. doi: 10.1038/s41408-021-00430-6.
4
Neurological adverse events following CAR T-cell therapy: a real-world analysis.CAR T 细胞治疗后的神经不良事件：真实世界分析。
Immunotherapy. 2020 Oct;12(14):1077-1082. doi: 10.2217/imt-2020-0161. Epub 2020 Aug 18.
5
Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: A meta-analysis.第二代嵌合抗原受体T细胞疗法治疗弥漫性大B细胞淋巴瘤的疗效与安全性：一项荟萃分析。
Mol Clin Oncol. 2020 Oct;13(4):33. doi: 10.3892/mco.2020.2103. Epub 2020 Jul 29.
6
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality.接受 CD19 CAR T 细胞治疗的 DLBCL 患者经历了高器官毒性负担，但非复发死亡率低。
Blood Adv. 2020 Jul 14;4(13):3024-3033. doi: 10.1182/bloodadvances.2020001972.
7
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.塞利尼索治疗复发或难治性弥漫性大B细胞淋巴瘤患者（SADAL）：一项单臂、跨国、多中心、开放标签的2期试验。
Lancet Haematol. 2020 Jul;7(7):e511-e522. doi: 10.1016/S2352-3026(20)30120-4.
8
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.塔法西单抗联合来那度胺治疗复发或难治性弥漫性大 B 细胞淋巴瘤（L-MIND）：一项多中心、前瞻性、单臂、2 期研究。
Lancet Oncol. 2020 Jul;21(7):978-988. doi: 10.1016/S1470-2045(20)30225-4. Epub 2020 Jun 5.
9
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.嵌合抗原受体修饰的自然杀伤细胞在 CD19 阳性淋巴肿瘤中的应用。
N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.
10
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.DuoBody-CD3xCD20 在临床前模型中可诱导强烈的 T 细胞介导的恶性 B 细胞杀伤作用，并为皮下给药提供了机会。
EBioMedicine. 2020 Feb;52:102625. doi: 10.1016/j.ebiom.2019.102625. Epub 2020 Jan 23.